|Home | English version | Mappa | Commenti | Sondaggio | Staff | Contattaci||Cerca nel sito|
|Istituto di scienza dell'alimentazione|
Contributo in rivista
Tipo: Articolo in rivista
Titolo: Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats.
Anno di pubblicazione: 2007
Autori: D'Argenio G, Petrosino S, Gianfrani C, Valenti M, Scaglione G, Grandone I, Nigam S, Sorrentini I, Mazzarella G, Di Marzo V.
Affiliazioni autori: G. D'Argenio : I. Grandone Dipartimento di Gastroenterologia, UniversitÓ di Napoli "Federico II", Naples, Italy S. Petrosino : M. Valenti : V. Di Marzo (*) Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy e-mail: firstname.lastname@example.org S. Petrosino Dipartimento di Scienze Farmaceutiche, UniversitÓ degli Studi di Salerno, Fisciano, Italy C. Gianfrani : G. Mazzarella Istituto di Scienze dell'Alimentazione, Consiglio Nazionale delle Ricerche, Avellino, Italy G. Scaglione : I. Sorrentini Gastroenterologia, A.O. "Rummo", Benevento, Italy S. Nigam Eicosanoid & Lipid Research Division, and Centre for Experimental Gynecology & Breast Research, University-Klinikum Benjamin Franklin, Free University Berlin, Berlin, Germany GIUSEPPE D'ARGENIO received his Ph.D. in Gastroenterological Sciences from the University of Rome "la Sapienza." After a postdoctoral fellowship with Prof. Fevery, University of Leuven, Belgium and an Assistant Professorship at the University of Naples, Italy, in Enzymology, he is presently leading the Laboratory for Research in Gastroenterology, Department of Clinical and Experimental Medicine at the School of Medicine, Federico II University of Naples, Italy. His research interests include enzymology, repairing process, and cell biology in gut inflammation. VINCENZO DI MARZO did a first degree in Chemistry at the University of Naples and completed a Ph.D. in biochemistry and molecular pharmacology at the Imperial College, London, UK, in 1988. He is Research Director at the Institute of Biomolecular Chemistry of the National Research Council in Pozzuoli, Naples, Italy, and Coordinator of the Endocannabinoid Research Group in the Naples Region. His research interests include the biosynthesis, metabolism, and physiopathological role of endocannabinoids and bioactive fatty acid
Abstract: The endocannabinoid system is upregulated in both human inflammatory bowel diseases and experimental models of colitis. In this study, we investigated whether this upregulation is a marker also of celiac disease-induced atrophy. The levels of the cannabinoid CB(1) receptor, of the endocannabinoids, anandamide, and 2-arachidonoyl-glycerol (2-AG), and of the anti-inflammatory mediator palmitoylethanolamide (PEA) were analyzed in bioptic samples from the duodenal mucosa of celiac patients at first diagnosis assessed by the determination of antiendomysial antibodies and histological examination. Samples were analyzed during the active phase of atrophy and after remission and compared to control samples from non-celiac patients. The levels of anandamide and PEA were significantly elevated (approx. 2- and 1.8-fold, respectively) in active celiac patients and so were those of CB(1) receptors. Anandamide levels returned to normal after remission with a gluten-free diet. We also analyzed endocannabinoid and PEA levels in the jejunum of rats 2, 3, and 7 days after treatment with methotrexate, which causes inflammatory features (assessed by histopathological analyses and myeloperoxidase activity) similar to those of celiac patients. In both muscle/serosa and mucosa layers, the levels of anandamide, 2-AG, and PEA peaked 3 days after treatment and returned to basal levels at remission, 7 days after treatment. Thus, intestinal endocannabinoid levels peak with atrophy and regress with remission in both celiac patients and methotrexate-treated rats. The latter might be used as a model to study the role of the endocannabinoid system in celiac disease.
Pagine da: 523
Pagine a: 530
Pagine totali: 8
Journal of molecular medicine
Numero volume: 85
Indicizzato da: ISI Web of Science (WOS) [WOS:000246204100011]
Altre informazioni: 10
|Home | Il CNR | I servizi | News | Eventi | Istituti | Focus|